Lilly Completes Acquisition of DICE Therapeutics INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands...
PASSAGE BIO ANNOUNCES PROMISING INTERIM CLINICAL DATA FROM FIRST EIGHT PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profile Dose 2...
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline Financing co-led by Redmile Group and Bain Capital Life Sciences Proceeds to support completion of Phase 2/3 registrational trial of ABC008, a first-in-class...
Recent Comments